Skip to content
ETopical – Lifestyle
Author:
Candel Therapeutics
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
September 30, 2026
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
September 10, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 1, 2026
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 13, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
August 3, 2026
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
July 29, 2026
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 8, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 1, 2026
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
June 30, 2026
←
Previous Page
1
2
3
Next Page
→